Mielóma multiplex: vizsgálatok itt: Finnország

In Finnország 11 Also abroad 703

11 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 10.. Ask the study team whether a trial fits you.

3. fázisTaking people
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Where
Helsinki, Kuopio
Életkor
18 év and over
People
810 worldwide
Run by
Celgene
See details and how to joinNCT05519085
3. fázisTaking people
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Where
Helsinki, Oulu, Turku
Életkor
18 év and over
People
440 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00
3. fázisTaking people
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Where
Helsinki, Kotka, Kuopio, Oulu, Turku
Életkor
18 év and over
People
1060 worldwide
Run by
Pfizer
See details and how to joinNCT05623020 · EU 2024-514139-50-00
2. fázisCsak meghívásos
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Where
Helsinki
Életkor
18 év and over
People
70 worldwide
Run by
Sanofi
See details and how to joinNCT05669989
3. fázisTaking people
A long-term follow-up study for patients treated with Galapagos CAR T cell therapies
Where
Helsinki
Életkor
18 év and over
People
309 worldwide
Run by
Lakefront Biotherapeutics
See details and how to join2023-510173-34-00 · EU 2023-510173-34-00
3. fázisTaking people
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Where
Helsinki, Kuopio, Oulu, Tampere, Turku
Életkor
18 év and over
People
893 worldwide
Run by
Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00
3. fázisTaking people
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Where
Helsinki, Kuopio, Oulu, Tampere, Turku
Életkor
18 év and over
People
492 worldwide
Run by
Pfizer
See details and how to joinNCT06152575 · EU 2023-507871-23-00
1/2. fázisTaking people
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Where
Helsinki, Kuopio, Tampere, Turku
Életkor
18 év and over
People
123 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT05714839 · EU 2022-501941-63-00
2. fázisNot yet taking people in Finnország
Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.
Where
Helsinki
Életkor
18 év and over
People
50 worldwide
Run by
Odense University Hospital
See details and how to joinNCT07757412 · EU 2025-522114-23-00
2. fázisTaking people
A multi-center, open-label, phase 2 study of Elranatamab in patients with high-risk smoldering multiple myeloma
Where
Helsinki
Életkor
18 év and over
People
105 worldwide
Run by
European Myeloma Network B.V.
See details and how to join2023-505775-70-00 · EU 2023-505775-70-00
3. fázisTaking people
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
Where
Helsinki, Kuopio
Életkor
18 év and over
People
1000 worldwide
Run by
European Myeloma Network B.V.
See details and how to joinNCT06932562 · EU 2024-519827-16-00